1 1492 145 DNA HYDROXYMETHYLATION BY TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE 1 AND 3 REGULATES NOCICEPTIVE SENSITIZATION IN A CHRONIC INFLAMMATORY PAIN MODEL. BACKGROUND: TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE CONVERTS 5-METHYLCYTOSINE IN DNA TO 5-HYDROXYMETHYLCYTOSINE, WHICH PLAYS AN IMPORTANT ROLE IN GENE TRANSCRIPTION. ALTHOUGH 5-HYDROXYMETHYLCYTOSINE IS ENRICHED IN MAMMALIAN NEURONS, ITS REGULATORY FUNCTION IN NOCICEPTIVE INFORMATION PROCESSING IS UNKNOWN. METHODS: THE GLOBAL LEVELS OF 5-HYDROXYMETHYLCYTOSINE AND TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE WERE MEASURED IN SPINAL CORDS IN MICE TREATED WITH COMPLETE FREUND'S ADJUVANT. IMMUNOBLOTTING, IMMUNOHISTOCHEMISTRY, AND BEHAVIORAL TESTS WERE USED TO EXPLORE THE DOWNSTREAM TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE-DEPENDENT SIGNALING PATHWAY. RESULTS: COMPLETE FREUND'S ADJUVANT-INDUCED NOCICEPTION INCREASED THE MEAN LEVELS (+/- SD) OF SPINAL 5-HYDROXYMETHYLCYTOSINE (178 +/- 34 VS. 100 +/- 21; P = 0.0019), TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE-1 (0.52 +/- 0.11 VS. 0.36 +/- 0.064; P = 0.0088), AND TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE-3 (0.61 +/- 0.13 VS. 0.39 +/- 0.08; P = 0.0083) COMPARED WITH LEVELS IN CONTROL MICE (N = 6/GROUP). THE KNOCKDOWN OF TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE-1 OR TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE-3 ALLEVIATED THERMAL HYPERALGESIA AND MECHANICAL ALLODYNIA, WHEREAS OVEREXPRESSION CYTOSINETHEM IN NAIVE MICE (N = 6/GROUP). DOWN-REGULATION OF SPINAL TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE-1 AND TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE-3 ALSO REVERSED THE INCREASES IN FOS EXPRESSION (123 +/- 26 VS. 294 +/- 6; P = 0.0031; AND 140 +/- 21 VS. 294 +/- 60; P = 0.0043, RESPECTIVELY; N = 6/GROUP), 5-HYDROXYMETHYLCYTOSINE LEVELS IN THE STAT3 PROMOTER (75 +/- 16.1 VS. 156 +/- 28.9; P = 0.0043; AND 91 +/- 19.1 VS. 156 +/- 28.9; P = 0.0066, RESPECTIVELY; N = 5/GROUP), AND CONSEQUENT STAT3 EXPRESSION (93 +/- 19.6 VS. 137 +/- 27.5; P = 0.035; AND 72 +/- 15.2 VS. 137 +/- 27.5; P = 0.0028, RESPECTIVELY; N = 5/GROUP) IN COMPLETE FREUND'S ADJUVANT-TREATED MICE. CONCLUSIONS: THIS STUDY REVEALS A NOVEL EPIGENETIC MECHANISM FOR TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE-1 AND TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE-3 IN THE MODULATION OF SPINAL NOCICEPTIVE INFORMATION VIA TARGETING OF STAT3. 2017 2 5976 36 TET1-DEPENDENT EPIGENETIC MODIFICATION OF BDNF EXPRESSION IN DORSAL HORN NEURONS MEDIATES NEUROPATHIC PAIN IN RATS. TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE 1 (TET1) MEDIATES THE CONVERSION OF 5-METHYLCYTOSINE (5 MC) TO 5-HYDROXYMETHYLCYTOSINE (5 HMC), HENCE PROMOTING DNA DEMETHYLATION. ALTHOUGH RECENT STUDIES HAVE LINKED THE DNA DEMETHYLATION OF SPECIFIC GENES TO PAIN HYPERSENSITIVITY, THE ROLE OF SPINAL TET1-DEPENDENT DNA DEMETHYLATION IN NOCICEPTION HYPERSENSITIVITY DEVELOPMENT REMAINS ELUSIVE. HERE, WE REPORT CORRELATED WITH BEHAVIORAL ALLODYNIA, SPINAL NERVE LIGATION (SNL) UPREGULATED TET1 EXPRESSION IN DORSAL HORN NEURONS THAT HYDROXYLATE 5 MC TO 5 HMC AT CPG DINUCLEOTIDES IN THE BDNF PROMOTER TO PROMOTE SPINAL BDNF EXPRESSION AT DAY 7 AFTER OPERATION. FOCAL KNOCKDOWN OF SPINAL TET1 EXPRESSION DECREASED TET1 BINDING AND 5 HMC ENRICHMENT, FURTHER INCREASED 5 MC ENRICHMENT AT CPG SITES IN THE BDNF PROMOTER AND DECREASED SPINAL BDNF EXPRESSION ACCOMPANIED BY THE ALLEVIATION OF THE DEVELOPED ALLODYNIA. MOREOVER, AT DAY 7 AFTER OPERATION, SNL-ENHANCED TET1 EXPRESSION ALSO INHIBITED THE BINDING OF DNA METHYLTRANSFERASES (DNMTS, I.E., DNMT1, DNMT3A, AND DNMT3B) TO THE BDNF PROMOTER, A REQUIREMENT FOR TRANSCRIPTIONAL SILENCING BY CATALYSING 5-CYTOSINE (5C) TO 5 MC. TOGETHER, THESE DATA SUGGEST AT CPG SITES OF THE BDNF PROMOTER, SNL-ENHANCED TET1 EXPRESSION PROMOTES DNA DEMETHYLATION BOTH BY CONVERTING 5 MC TO 5 HMC AND INHIBITING DNMT BINDING TO REGULATE SPINAL BDNF EXPRESSION, HENCE CONTRIBUTING TO BEHAVIORAL ALLODYNIA DEVELOPMENT. 2016 3 3433 48 HYDROXYMETHYLATION OF MICRORNA-365-3P REGULATES NOCICEPTIVE BEHAVIORS VIA KCNH2. DNA 5-HYDROXYLMETHYLCYTOSINE (5HMC) CATALYZED BY TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE (TET) OCCURS ABUNDANTLY IN NEURONS OF MAMMALS. HOWEVER, THE IN VIVO CAUSAL LINK BETWEEN TET DYSREGULATION AND NOCICEPTIVE MODULATION HAS NOT BEEN ESTABLISHED. HERE, WE FOUND THAT SPINAL TET1 AND TET3 WERE SIGNIFICANTLY INCREASED IN THE MODEL OF FORMALIN-INDUCED ACUTE INFLAMMATORY PAIN, WHICH WAS ACCOMPANIED WITH THE AUGMENT OF GENOME-WIDE 5HMC CONTENT IN SPINAL CORD. KNOCKDOWN OF SPINAL TET1 OR TET3 ALLEVIATED THE FORMALIN-INDUCED NOCICEPTIVE BEHAVIOR AND OVEREXPRESSION OF SPINAL TET1 OR TET3 IN NAIVE MICE PRODUCED PAIN-LIKE BEHAVIOR AS EVIDENCED BY DECREASED THERMAL PAIN THRESHOLD. FURTHERMORE, WE FOUND THAT TET1 OR TET3 REGULATED THE NOCICEPTIVE BEHAVIOR BY TARGETING MICRORNA-365-3P (MIR-365-3P). FORMALIN INCREASED 5HMC IN THE MIR-365-3P PROMOTER, WHICH WAS INHIBITED BY KNOCKDOWN OF TET1 OR TET3 AND MIMICKED BY OVEREXPRESSION OF TET1 OR TET3 IN NAIVE MICE. NOCICEPTIVE BEHAVIOR INDUCED BY FORMALIN OR OVEREXPRESSION OF SPINAL TET1 OR TET3 COULD BE PREVENTED BY DOWNREGULATION OF MIR-365-3P, AND MIMICKED BY OVEREXPRESSION OF SPINAL MIR-365-3P. FINALLY, WE DEMONSTRATED THAT A POTASSIUM CHANNEL, VOLTAGE-GATED EAG-RELATED SUBFAMILY H MEMBER 2 (KCNH2), VALIDATED AS A TARGET OF MIR-365-3P, PLAYED A CRITICAL ROLE IN NOCICEPTIVE MODULATION BY SPINAL TET OR MIR-365-3P. TOGETHER, WE CONCLUDED THAT TET-MEDIATED HYDROXYMETHYLATION OF MIR-365-3P REGULATES NOCICEPTIVE BEHAVIOR VIA KCNH2. SIGNIFICANCE STATEMENT: MOUNTING EVIDENCE INDICATES THAT EPIGENETIC MODIFICATIONS IN THE NOCICEPTIVE PATHWAY CONTRIBUTE TO PAIN PROCESSES AND ANALGESIA RESPONSE. HERE, WE FOUND THAT THE INCREASE OF 5HMC CONTENT MEDIATED BY TET1 OR TET3 IN MIR-365-3P PROMOTER IN THE SPINAL CORD IS INVOLVED IN NOCICEPTIVE MODULATION THROUGH TARGETING A POTASSIUM CHANNEL, KCNH2. OUR STUDY REVEALS A NEW EPIGENETIC MECHANISM UNDERLYING NOCICEPTIVE INFORMATION PROCESSING, WHICH MAY BE A NOVEL TARGET FOR DEVELOPMENT OF ANTINOCICEPTIVE DRUGS. 2016 4 4172 35 MELATONIN IMPEDES TET1-DEPENDENT MGLUR5 PROMOTER DEMETHYLATION TO RELIEVE PAIN. MELATONIN (N-ACETYL-5-METHOXYTRYPTAMINE)/MT2 RECEPTOR-DEPENDENT EPIGENETIC MODIFICATION REPRESENTS A NOVEL PATHWAY IN THE TREATMENT OF NEUROPATHIC PAIN. BECAUSE SPINAL TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE 1 (TET1)-DEPENDENT EPIGENETIC DEMETHYLATION HAS RECENTLY BEEN LINKED TO PAIN HYPERSENSITIVITY, WE HYPOTHESIZED THAT MELATONIN/MT2-DEPENDENT ANALGESIA INVOLVES SPINAL TET1-DEPENDENT DEMETHYLATION. HERE, WE SHOWED THAT SPINAL TET1 GENE TRANSFER BY INTRATHECAL DELIVERY OF TET1-ENCODING VECTORS TO NAIVE RATS PRODUCED PROFOUND AND LONG-LASTING NOCICEPTIVE HYPERSENSITIVITY. IN ADDITION, ENHANCED TET1 EXPRESSION, TET1-METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 5 (MGLUR5) PROMOTER COUPLING, DEMETHYLATION AT THE MGLUR5 PROMOTER, AND MGLUR5 EXPRESSION IN DORSAL HORN NEURONS WERE OBSERVED. RATS SUBJECTED TO SPINAL NERVE LIGATION AND INTRAPLANTAR COMPLETE FREUND'S ADJUVANT INJECTION DISPLAYED TACTILE ALLODYNIA AND BEHAVIORAL HYPERALGESIA ASSOCIATED WITH SIMILAR CHANGES IN THE DORSAL HORN. NOTABLY, INTRATHECAL MELATONIN INJECTION REVERSED THE PROTEIN EXPRESSION, PROTEIN-PROMOTER COUPLING, PROMOTER DEMETHYLATION, AND PAIN HYPERSENSITIVITY INDUCED BY TET1 GENE TRANSFER, SPINAL NERVE LIGATION, AND INTRAPLANTAR COMPLETE FREUND'S ADJUVANT INJECTION. ALL THE EFFECTS CAUSED BY MELATONIN WERE BLOCKED BY PRETREATMENT WITH A MT2 RECEPTOR-SELECTIVE ANTAGONIST. IN CONCLUSION, MELATONIN RELIEVES PAIN BY IMPEDING TET1-DEPENDENT DEMETHYLATION OF MGLUR5 IN DORSAL HORN NEURONS THROUGH THE MT2 RECEPTOR. OUR FINDINGS LINK MELATONIN/MT2 SIGNALING TO TET1-DEPENDENT EPIGENETIC DEMETHYLATION OF NOCICEPTIVE GENES FOR THE FIRST TIME AND SUGGEST MELATONIN AS A PROMISING THERAPY FOR THE TREATMENT OF PAIN. 2017 5 21 24 5-HYDROXYMETHYLCYTOSINE (5HMC) AND TEN-ELEVEN TRANSLOCATION 1-3 (TET1-3) PROTEINS IN THE DORSAL ROOT GANGLIA OF MOUSE: EXPRESSION AND DYNAMIC REGULATION IN NEUROPATHIC PAIN. EPIGENETIC MECHANISMS ARE INCREASINGLY IMPLICATED IN CHRONIC PAIN PATHOLOGY. IN THIS STUDY, WE DEMONSTRATE THAT THE NOVEL EPIGENETIC MARK 5-HYDROXYMETHYLCYTOSINE (5HMC) IS PRESENT IN DORSAL ROOT GANGLIA (DRG) NEURONS AND GLIA, AND ITS LEVELS INCREASE FOLLOWING NERVE INJURY. FURTHERMORE, WE SHOW THAT THE 5HMC-GENERATING TEN-ELEVEN TRANSLOCATION 1-3 (TET1-3) PROTEINS ARE EXPRESSED IN A CELL-TYPE SPECIFIC MANNER IN THE DRG, WITH TET3 DISPLAYING DIFFERENTIAL UPREGULATION AFTER INJURY, SUGGESTING A POTENTIAL ROLE IN NEUROPATHIC PAIN. 2017 6 579 33 BEHAVIORAL AND MOLECULAR NEUROEPIGENETIC ALTERATIONS IN PRENATALLY STRESSED MICE: RELEVANCE FOR THE STUDY OF CHROMATIN REMODELING PROPERTIES OF ANTIPSYCHOTIC DRUGS. WE HAVE RECENTLY REPORTED THAT MICE BORN FROM DAMS STRESSED DURING PREGNANCY (PRS MICE), IN ADULTHOOD, HAVE BEHAVIORAL DEFICITS REMINISCENT OF BEHAVIORS OBSERVED IN SCHIZOPHRENIA (SZ) AND BIPOLAR (BP) DISORDER PATIENTS. FURTHERMORE, WE HAVE SHOWN THAT THE FRONTAL CORTEX (FC) AND HIPPOCAMPUS OF ADULT PRS MICE, LIKE THAT OF POSTMORTEM CHRONIC SZ PATIENTS, ARE CHARACTERIZED BY INCREASES IN DNA-METHYLTRANSFERASE 1 (DNMT1), TEN-ELEVEN METHYLCYTOSINE DIOXYGENASE 1 (TET1) AND EXHIBIT AN ENRICHMENT OF 5-METHYLCYTOSINE (5MC) AND 5-HYDROXYMETHYLCYTOSINE (5HMC) AT NEOCORTICAL GABAERGIC AND GLUTAMATERGIC GENE PROMOTERS. HERE, WE SHOW THAT THE BEHAVIORAL DEFICITS AND THE INCREASED 5MC AND 5HMC AT GLUTAMIC ACID DECARBOXYLASE 67 (GAD1), REELIN (RELN) AND BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) PROMOTERS AND THE REDUCED EXPRESSION OF THE MESSENGER RNAS (MRNAS) AND PROTEINS CORRESPONDING TO THESE GENES IN FC OF ADULT PRS MICE IS REVERSED BY TREATMENT WITH CLOZAPINE (5 MG KG(-1) TWICE A DAY FOR 5 DAYS) BUT NOT BY HALOPERIDOL (1 MG KG(-1) TWICE A DAY FOR 5 DAYS). INTERESTINGLY, CLOZAPINE HAD NO EFFECT ON EITHER THE BEHAVIOR, PROMOTER METHYLATION OR THE EXPRESSION OF THESE MRNAS AND PROTEINS WHEN ADMINISTERED TO OFFSPRING OF NONSTRESSED PREGNANT MICE. CLOZAPINE, BUT NOT HALOPERIDOL, REDUCED THE ELEVATED LEVELS OF DNMT1 AND TET1, AS WELL AS THE ELEVATED LEVELS OF DNMT1 BINDING TO GAD1, RELN AND BDNF PROMOTERS IN PRS MICE SUGGESTING THAT CLOZAPINE, UNLIKE HALOPERIDOL, MAY LIMIT DNA METHYLATION BY INTERFERING WITH DNA METHYLATION DYNAMICS. WE CONCLUDE THAT THE PRS MOUSE MODEL MAY BE USEFUL PRECLINICALLY IN SCREENING FOR THE POTENTIAL EFFICACY OF ANTIPSYCHOTIC DRUGS ACTING ON ALTERED EPIGENETIC MECHANISMS. FURTHERMORE, PRS MICE MAY BE INVALUABLE FOR UNDERSTANDING THE ETIOPATHOGENESIS OF SZ AND BP DISORDER AND FOR PREDICTING TREATMENT RESPONSES AT EARLY STAGES OF THE ILLNESS ALLOWING FOR EARLY DETECTION AND REMEDIAL INTERVENTION. 2016 7 434 41 ANTIDEPRESSANT-LIKE EFFECT OF SODIUM BUTYRATE IS ASSOCIATED WITH AN INCREASE IN TET1 AND IN 5-HYDROXYMETHYLATION LEVELS IN THE BDNF GENE. BACKGROUND: EPIGENETIC DRUGS LIKE SODIUM BUTYRATE (NAB) SHOW ANTIDEPRESSANT-LIKE EFFECTS IN PRECLINICAL STUDIES, BUT THE EXACT MOLECULAR MECHANISMS OF THE ANTIDEPRESSANT EFFECTS REMAIN UNKNOWN. WHILE RESEARCH USING NAB HAS MAINLY FOCUSED ON ITS ROLE AS A HISTONE DEACETYLASE INHIBITOR (HDACI), THERE IS ALSO EVIDENCE THAT NAB AFFECTS DNA METHYLATION. METHODS: THE PURPOSE OF THIS STUDY WAS TO EXAMINE NAB'S PUTATIVE ANTIDEPRESSANT-LIKE EFFICACY IN RELATION TO DNA METHYLATION CHANGES IN THE PREFRONTAL CORTEX OF AN ESTABLISHED GENETIC RAT MODEL OF DEPRESSION (THE FLINDERS SENSITIVE LINE [FSL]) AND ITS CONTROLS (THE FLINDERS RESISTANT LINE). RESULTS: THE FSL RATS HAD LOWER LEVELS OF TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE 1 (TET1), WHICH CATALYZES THE CONVERSION OF DNA METHYLATION TO HYDROXYMETHYLATION. AS INDICATED BY THE BEHAVIORAL DESPAIR TEST, CHRONIC ADMINISTRATION OF NAB HAD ANTIDEPRESSANT-LIKE EFFECTS IN THE FSL AND WAS ACCOMPANIED BY INCREASED LEVELS OF TET1. THE TET1 UPREGULATION WAS ALSO ASSOCIATED WITH AN INCREASE OF HYDROXYMETHYLATION AND A DECREASE OF METHYLATION IN BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF), A GENE ASSOCIATED WITH NEUROGENESIS AND SYNAPTIC PLASTICITY. THESE EPIGENETIC CHANGES WERE ASSOCIATED WITH A CORRESPONDING BDNF OVEREXPRESSION. CONCLUSIONS: OUR DATA SUPPORT THE ANTIDEPRESSANT EFFICACY OF HDACIS AND SUGGEST THAT THEIR EPIGENETIC EFFECTS MAY ALSO INCLUDE DNA METHYLATION CHANGES THAT ARE MEDIATED BY DEMETHYLATION-FACILITATING ENZYMES LIKE TET1. 2014 8 2111 27 EPIGENETIC FUNCTION OF TET FAMILY, 5-METHYLCYTOSINE, AND 5-HYDROXYMETHYLCYTOSINE IN HEMATOLOGIC MALIGNANCIES. DNA METHYLATION PLAYS SIGNIFICANT ROLES IN A VARIETY OF BIOLOGICAL AND PATHOLOGICAL PROCESSES INCLUDING MAMMALIAN DEVELOPMENT, GENOMIC IMPRINTING, RETROTRANSPOSON SILENCING, AND X-CHROMOSOME INACTIVATION. RECENT DISCOVERIES INDICATED THAT TEN-ELEVEN TRANSLOCATION (TET) FAMILY OF DIOXYGENASES CAN CONVERT 5-METHYLCYTOSINE (5-MC) INTO 5-HYDROXYMETHYLCYTOSINE (5-HMC). THE TET FAMILY INCLUDES THREE MEMBERS: TET1, TET2, AND TET3. WITH INCREASING EVIDENCE, MORE AND MORE BIOLOGICAL AND PATHOLOGICAL PROCESSES IN WHICH 5-HMC AND TET FAMILY SERVE UNPARALLELED BIOLOGICAL ROLES ARE NOTICED, FOR EXAMPLE, DNA DEMETHYLATION AND TRANSCRIPTIONAL REGULATION OF DIFFERENT TARGET GENES, WHICH ARE INVOLVED IN MANY HUMAN DISEASES, ESPECIALLY HEMATOLOGIC MALIGNANCIES, RESEMBLING CHRONIC MYELOMONOCYTIC LEUKEMIA, MYELODYSPLASTIC SYNDROMES, AND SO ON. IN THIS REVIEW, WE FOCUS ON THE DIVERSE FUNCTIONS OF TET FAMILY AND THE NOVEL EPIGENETIC MARKS, 5-MC AND 5-HMC, IN HEMATOLOGIC MALIGNANCIES. THIS REVIEW WILL PROVIDE VALUABLE INSIGHTS INTO THE POTENTIAL TARGETS OF HEMATOLOGIC MALIGNANCIES. FURTHER UNDERSTANDING OF THE NORMAL AND PATHOLOGICAL FUNCTIONS OF TET FAMILY MAY PROVIDE NEW METHODS TO DEVELOP NOVEL EPIGENETIC THERAPIES FOR TREATING HEMATOLOGIC MALIGNANCIES. 2019 9 5973 27 TET-CATALYZED 5-HYDROXYMETHYLATION PRECEDES HNF4A PROMOTER CHOICE DURING DIFFERENTIATION OF BIPOTENT LIVER PROGENITORS. UNDERSTANDING THE PROCESSES THAT GOVERN LIVER PROGENITOR CELL DIFFERENTIATION HAS IMPORTANT IMPLICATIONS FOR THE DESIGN OF STRATEGIES TARGETING CHRONIC LIVER DISEASES, WHEREBY REGENERATION OF LIVER TISSUE IS CRITICAL. ALTHOUGH DNA METHYLATION (5MC) AND HYDROXYMETHYLATION (5HMC) ARE HIGHLY DYNAMIC DURING EARLY EMBRYONIC DEVELOPMENT, LESS IS KNOWN ABOUT THEIR ROLES AT LATER STAGES OF DIFFERENTIATION. USING AN IN VITRO MODEL OF HEPATOCYTE DIFFERENTIATION, WE SHOW HERE THAT 5HMC PRECEDES THE EXPRESSION OF PROMOTER 1 (P1)-DEPENDENT ISOFORMS OF HNF4A, A MASTER TRANSCRIPTION FACTOR OF HEPATOCYTE IDENTITY. 5HMC AND HNF4A EXPRESSION FROM P1 ARE DEPENDENT ON TEN-ELEVEN TRANSLOCATION (TET) DIOXYGENASES. IN TURN, THE LIVER PIONEER FACTOR FOXA2 IS NECESSARY FOR TET1 BINDING TO THE P1 LOCUS. BOTH FOXA2 AND TETS ARE REQUIRED FOR THE 5HMC-RELATED SWITCH IN HNF4A EXPRESSION. THE EPIGENETIC EVENT IDENTIFIED HERE MAY BE A KEY STEP FOR THE ESTABLISHMENT OF THE HEPATOCYTE PROGRAM BY HNF4A. 2017 10 5974 33 TET1 IN NUCLEUS ACCUMBENS OPPOSES DEPRESSION- AND ANXIETY-LIKE BEHAVIORS. DEPRESSION IS A LEADING CAUSE OF DISEASE BURDEN, YET CURRENT THERAPIES FULLY TREAT <50% OF AFFECTED INDIVIDUALS. INCREASING EVIDENCE IMPLICATES EPIGENETIC MECHANISMS IN DEPRESSION AND ANTIDEPRESSANT ACTION. HERE WE EXAMINED A POSSIBLE ROLE FOR THE DNA DIOXYGENASE, TEN-ELEVEN TRANSLOCATION PROTEIN 1 (TET1), IN DEPRESSION-RELATED BEHAVIORAL ABNORMALITIES. WE APPLIED CHRONIC SOCIAL DEFEAT STRESS, AN ETHOLOGICALLY VALIDATED MOUSE MODEL OF DEPRESSION-LIKE BEHAVIORS, AND EXAMINED TET1 EXPRESSION CHANGES IN NUCLEUS ACCUMBENS (NAC), A KEY BRAIN REWARD REGION. WE SHOW DECREASED TET1 EXPRESSION IN NAC IN STRESS-SUSCEPTIBLE MICE ONLY. SURPRISINGLY, SELECTIVE KNOCKOUT OF TET1 IN NAC NEURONS OF ADULT MICE PRODUCED ANTIDEPRESSANT-LIKE EFFECTS IN SEVERAL BEHAVIORAL ASSAYS. TO IDENTIFY TET1 TARGETS THAT MEDIATE THESE ACTIONS, WE PERFORMED RNASEQ ON NAC AFTER CONDITIONAL DELETION OF TET1 AND FOUND THAT IMMUNE-RELATED GENES ARE THE MOST HIGHLY DYSREGULATED. MOREOVER, MANY OF THESE GENES ARE ALSO UPREGULATED IN THE NAC OF RESILIENT MICE AFTER CHRONIC SOCIAL DEFEAT STRESS. THESE FINDINGS REVEAL A NOVEL ROLE FOR TET1, AN ENZYME IMPORTANT FOR DNA HYDROXYMETHYLATION, IN THE BRAIN'S REWARD CIRCUITRY IN MODULATING STRESS RESPONSES IN MICE. WE ALSO IDENTIFY A SUBSET OF GENES THAT ARE REGULATED BY TET1 IN THIS CIRCUITRY. THESE FINDINGS PROVIDE NEW INSIGHT INTO THE PATHOPHYSIOLOGY OF DEPRESSION, WHICH CAN AID IN FUTURE ANTIDEPRESSANT DRUG DISCOVERY EFFORTS. 2017 11 5977 30 TET1-TRPV4 SIGNALING CONTRIBUTES TO BONE CANCER PAIN IN RATS. BONE CANCER PAIN (BCP) IS EXCRUCIATING FOR CANCER PATIENTS, WITH LIMITED CLINICAL TREATMENT OPTIONS AND SIGNIFICANT SIDE EFFECTS, DUE TO THE COMPLEX AND UNCLEAR PATHOGENESIS OF BONE CANCER PAIN. PERIPHERAL SENSITIZATION IN DORSAL ROOT GANGLION (DRG) NEURONS IS A RECOGNIZED CELLULAR MECHANISM FOR BONE CANCER PAIN. THE PATHOLOGICAL MECHANISM OF CHRONIC PAIN IS INCREASINGLY BEING AFFECTED BY EPIGENETIC MECHANISMS. IN THIS STUDY, WE UNBIASEDLY SHOWED THAT THE DNA HYDROXYMETHYLASE TEN-ELEVEN TRANSLOCATION 1 (TET1) EXPRESSION WAS SIGNIFICANTLY INCREASED IN THE L4-6 DRG OF BCP RATS AND TEN-ELEVEN TRANSLOCATION 2 (TET2) EXPRESSION DID NOT CHANGE SIGNIFICANTLY. NOTABLY, TET1 INHIBITION BY INTRATHECAL INJECTION OF BOBCAT339 (A TET1 INHIBITOR) EFFECTIVELY RELIEVED MECHANICAL HYPERALGESIA IN BCP RATS. PERIPHERAL SENSITIZATION IN CHRONIC PAIN RELIES ON THE ACTIVATION AND OVEREXPRESSION OF ION CHANNELS ON NEURONS. HERE, WE DEMONSTRATED THAT TRPV4, ONE OF THE TRANSIENT RECEPTOR POTENTIAL ION CHANNEL FAMILY MEMBERS, WAS SIGNIFICANTLY ELEVATED IN THE L4-6 DRG OF BCP RATS. IN ADDITION, TRPV4 INHIBITION BY INTRATHECAL INJECTION OF HC067047 (A TRPV4 INHIBITOR) ALSO SIGNIFICANTLY ATTENUATED MECHANICAL HYPERALGESIA IN BCP RATS. INTERESTINGLY, WE FOUND THAT TET1 INHIBITION DOWNREGULATED TRPV4 EXPRESSION IN THE L4-6 DRG OF BCP RATS. AS A RESULT, THESE FINDINGS SUGGESTED THAT TET1 MAY CONTRIBUTE TO BONE CANCER PAIN BY UPREGULATING TRPV4 EXPRESSION IN THE L4-6 DRG OF BCP RATS AND THAT TET1 OR TRPV4 MAY BECOME THERAPEUTIC TARGETS FOR BONE CANCER PAIN. 2023 12 4212 31 METHAMPHETAMINE DOWNREGULATES STRIATAL GLUTAMATE RECEPTORS VIA DIVERSE EPIGENETIC MECHANISMS. BACKGROUND: CHRONIC METHAMPHETAMINE (METH) EXPOSURE CAUSES NEUROADAPTATIONS AT GLUTAMATERGIC SYNAPSES. METHODS: TO IDENTIFY THE METH-INDUCED EPIGENETIC UNDERPINNINGS OF THESE NEUROADAPTATIONS, WE INJECTED INCREASING METH DOSES TO RATS FOR 2 WEEKS AND MEASURED STRIATAL GLUTAMATE RECEPTOR EXPRESSION. WE THEN QUANTIFIED THE EFFECTS OF METH EXPOSURE ON HISTONE ACETYLATION. WE ALSO MEASURED METH-INDUCED CHANGES IN DNA METHYLATION AND DNA HYDROXYMETHYLATION. RESULTS: CHRONIC METH DECREASED TRANSCRIPT AND PROTEIN EXPRESSION OF GLUA1 AND GLUA2 ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLE PROPIONIC ACID RECEPTOR (AMPAR) AND GLUN1 N-METHYL-D-ASPARTATE RECEPTOR SUBUNITS. THESE CHANGES WERE ASSOCIATED WITH ALTERED ELECTROPHYSIOLOGICAL GLUTAMATERGIC RESPONSES IN STRIATAL NEURONS. CHROMATIN IMMUNOPRECIPITATION-POLYMERASE CHAIN REACTION REVEALED THAT METH DECREASED ENRICHMENT OF ACETYLATED HISTONE H4 ON GLUA1, GLUA2, AND GLUN1 PROMOTERS. METHAMPHETAMINE EXPOSURE ALSO INCREASED REPRESSOR ELEMENT-1 SILENCING TRANSCRIPTION FACTOR (REST) COREPRESSOR 1, METHYLATED CPG BINDING PROTEIN 2, AND HISTONE DEACETYLASE 2 ENRICHMENT, BUT NOT OF SIRTUIN 1 OR SIRTUIN 2, ONTO GLUA1 AND GLUA2 GENE SEQUENCES. MOREOVER, METH CAUSED INTERACTIONS OF REST COREPRESSOR 1 AND METHYLATED CPG BINDING PROTEIN 2 WITH HISTONE DEACETYLASE 2 AND OF REST WITH HISTONE DEACETYLASE 1. SURPRISINGLY, METHYLATED DNA IMMUNOPRECIPITATION AND HYDROXYMETHYLATED DNA IMMUNOPRECIPITATION-POLYMERASE CHAIN REACTION REVEALED METH-INDUCED DECREASED ENRICHMENT OF 5-METHYLCYTOSINE AND 5-HYDROXYMETHYLCYTOSINE AT GLUA1 AND GLUA2 PROMOTER SEQUENCES. IMPORTANTLY, THE HISTONE DEACETYLASE INHIBITOR, VALPROIC ACID, BLOCKED METH-INDUCED DECREASED EXPRESSION OF AMPAR AND N-METHYL-D-ASPARTATE RECEPTOR SUBUNITS. FINALLY, VALPROIC ACID ALSO ATTENUATED METH-INDUCED DECREASE H4K16AC RECRUITMENT ON AMPAR GENE SEQUENCES. CONCLUSIONS: THESE OBSERVATIONS SUGGEST THAT HISTONE H4 HYPOACETYLATION MAY BE THE MAIN DETERMINANT OF METH-INDUCED DECREASED STRIATAL GLUTAMATE RECEPTOR EXPRESSION. 2014 13 1268 29 CYTOPLASMATIC COMPARTMENTALIZATION BY BCR-ABL PROMOTES TET2 LOSS-OF-FUNCTION IN CHRONIC MYELOID LEUKEMIA. THE LOSS-OF-FUNCTION OF TEN-ELEVEN-TRANSLOCATION (TET) 2, A FE(2+) -OXOGLUTARATE-DEPENDENT DIOXYGENASE CATALYZING 5 METHYL CYTOSINE (5MC) CONVERSION INTO 5-HYDROXYMETHYLCYTOSINE (5HMC), CONTRIBUTES TO THE HEMATOPOIETIC TRANSFORMATION IN VIVO. THE AIM OF OUR STUDY WAS TO ELUCIDATE ITS ROLE IN THE PHENOTYPE OF CHRONIC MYELOID LEUKEMIA (CML), A MYELOPROLIFERATIVE DISEASE CAUSED BY THE BCR-ABL REARRANGED GENE. WE FIRST CONFIRMED TET2 INTERACTION WITH THE BCR-ABL PROTEIN PREDICTED BY A FOURIER-BASED BIOINFORMATIC METHOD. SUCH INTERACTION LED TO TET2 CYTOPLASMATIC COMPARTMENTALIZATION IN A COMPLEX TETHERED BY THE FUSION PROTEIN TYROSINE KINASE (TK) AND ENCOMPASSING THE FORKHEAD BOX O3A (FOXO3A) TRANSCRIPTION FACTOR. WE THEN FOCUSED THE IMPACT OF TET2 LOSS-OF-FUNCTION ON EPIGENETIC TRANSCRIPTIONAL REGULATION OF BCL2-INTERACTING MEDIATOR (BIM), A PRO-APOPTOTIC PROTEIN TRANSCRIPTIONALLY REGULATED BY FOXO3A. BIM DOWNREGULATION IS A CRITICAL COMPONENT OF CML PROGENITOR EXTENDED SURVIVAL AND IS ALSO INVOLVED IN THE DISEASE RESISTANCE TO IMATINIB (IM). HERE WE REPORTED THAT TET2 RELEASE FROM BCR-ABL PROTEIN FOLLOWING TK INHIBITION IN RESPONSE TO IM TRIGGERS A CHAIN OF EVENTS INCLUDING TET2 NUCLEAR TRANSLOCATION, RE-ACTIVATION OF ITS ENZYMATIC FUNCTION AT 5MC AND RECRUITMENT AT THE BIM PROMOTER FOLLOWED BY BIM TRANSCRIPTIONAL INDUCTION. 5HMC INCREMENT FOLLOWING TET2 RE-ACTIVATION WAS ASSOCIATED WITH THE REDUCTION OF HISTONE H3 TRI-METHYLATION AT LYSINE 9 (H3K9ME3), WHICH MAY CONTRIBUTE WITH DNA DE-METHYLATION REPORTED ELSEWHERE TO RECAST A PERMISSIVE EPIGENETIC "LANDSCAPE" FOR FOXO3A TRANSCRIPTIONAL ACTIVITY. 2012 14 3729 36 INHIBITION OF TET1 PREVENTS THE DEVELOPMENT OF OSTEOARTHRITIS AND REVEALS THE 5HMC LANDSCAPE THAT ORCHESTRATES PATHOGENESIS. OSTEOARTHRITIS (OA) IS A DEGENERATIVE DISEASE OF THE JOINT, WHICH RESULTS IN PAIN, LOSS OF MOBILITY, AND, EVENTUALLY, JOINT REPLACEMENT. CURRENTLY, NO DISEASE-MODIFYING DRUGS EXIST, PARTLY BECAUSE OF THE MULTIPLE LEVELS AT WHICH CARTILAGE HOMEOSTASIS IS DISRUPTED. RECENT STUDIES HAVE HIGHLIGHTED THE IMPORTANCE OF EPIGENETIC DYSREGULATION IN OA, SPARKING INTEREST IN THE EPIGENETIC MODULATION FOR THIS DISEASE. IN OUR PREVIOUS WORK, WE CHARACTERIZED A FIVEFOLD INCREASE IN CYTOSINE HYDROXYMETHYLATION (5HMC), AN OXIDIZED DERIVATIVE OF CYTOSINE METHYLATION (5MC) ASSOCIATED WITH GENE ACTIVATION, ACCUMULATING AT OA-ASSOCIATED GENES. TO TEST THE ROLE OF 5HMC IN OA, HERE, WE USED A MOUSE MODEL OF SURGICALLY INDUCED OA AND FOUND THAT OA ONSET WAS ACCOMPANIED BY A GAIN OF ~40,000 DIFFERENTIALLY HYDROXYMETHYLATED SITES BEFORE THE NOTABLE HISTOLOGICAL APPEARANCE OF DISEASE. WE DEMONSTRATED THAT TEN-ELEVEN-TRANSLOCATION ENZYME 1 (TET1) MEDIATES THE 5HMC DEPOSITION BECAUSE 98% OF SITES ENRICHED FOR 5HMC IN OA WERE LOST IN TET1(-/-) MICE. LOSS OF TET1-MEDIATED 5HMC PROTECTED THE TET1(-/-) MICE FROM OA DEVELOPMENT, INCLUDING DEGENERATION OF THE CARTILAGE SURFACE AND OSTEOPHYTE FORMATION, BY DIRECTLY PREVENTING THE ACTIVATION OF MULTIPLE OA PATHWAYS. LOSS OF TET1 IN HUMAN OA CHONDROCYTES REDUCED THE EXPRESSION OF THE MATRIX METALLOPROTEINASES MMP3 AND MMP13 AND MULTIPLE INFLAMMATORY CYTOKINES. INTRA-ARTICULAR INJECTIONS OF A DIOXYGENASES INHIBITOR, 2-HYDROXYGLUTARATE, ON MICE AFTER SURGICAL INDUCTION OF OA STALLED DISEASE PROGRESSION. TREATMENT OF HUMAN OA CHONDROCYTES WITH THE SAME INHIBITOR ALSO PHENOCOPIED TET1 LOSS. COLLECTIVELY, THESE DATA DEMONSTRATE THAT TET1-MEDIATED 5HMC DEPOSITION REGULATES MULTIPLE OA PATHWAYS AND CAN BE MODULATED FOR THERAPEUTIC INTERVENTION. 2020 15 5965 24 TEN-ELEVEN-TRANSLOCATION 2 (TET2) NEGATIVELY REGULATES HOMEOSTASIS AND DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS IN MICE. THE TEN-ELEVEN-TRANSLOCATION 2 (TET2) GENE ENCODES A MEMBER OF TET FAMILY ENZYMES THAT ALTERS THE EPIGENETIC STATUS OF DNA BY OXIDIZING 5-METHYLCYTOSINE TO 5-HYDROXYMETHYLCYTOSINE (5HMC). SOMATIC LOSS-OF-FUNCTION MUTATIONS OF TET2 ARE FREQUENTLY OBSERVED IN PATIENTS WITH DIVERSE MYELOID MALIGNANCIES, INCLUDING MYELODYSPLASTIC SYNDROMES, MYELOPROLIFERATIVE NEOPLASMS, AND CHRONIC MYELOMONOCYTIC LEUKEMIA. BY ANALYZING MICE WITH TARGETED DISRUPTION OF THE TET2 CATALYTIC DOMAIN, WE SHOW HERE THAT TET2 IS A CRITICAL REGULATOR OF SELF-RENEWAL AND DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS (HSCS). TET2 DEFICIENCY LED TO DECREASED GENOMIC LEVELS OF 5HMC AND AUGMENTED THE SIZE OF THE HEMATOPOIETIC STEM/PROGENITOR CELL POOL IN A CELL-AUTONOMOUS MANNER. IN COMPETITIVE TRANSPLANTATION ASSAYS, TET2-DEFICIENT HSCS WERE CAPABLE OF MULTILINEAGE RECONSTITUTION AND POSSESSED A COMPETITIVE ADVANTAGE OVER WILD-TYPE HSCS, RESULTING IN ENHANCED HEMATOPOIESIS INTO BOTH LYMPHOID AND MYELOID LINEAGES. IN VITRO, TET2 DEFICIENCY DELAYED HSC DIFFERENTIATION AND SKEWED DEVELOPMENT TOWARD THE MONOCYTE/MACROPHAGE LINEAGE. OUR DATA INDICATE THAT TET2 HAS A CRITICAL ROLE IN REGULATING THE EXPANSION AND FUNCTION OF HSCS, PRESUMABLY BY CONTROLLING 5HMC LEVELS AT GENES IMPORTANT FOR THE SELF-RENEWAL, PROLIFERATION, AND DIFFERENTIATION OF HSCS. 2011 16 5617 37 SARCOSINE SUPPRESSES EPILEPTOGENESIS IN RATS WITH EFFECTS ON HIPPOCAMPAL DNA METHYLATION. EPILEPTOGENESIS IS A COMMON CONSEQUENCE OF BRAIN INSULTS, HOWEVER, THE PREVENTION OR DELAY OF THE EPILEPTOGENIC PROCESS REMAINS AN IMPORTANT UNMET MEDICAL CHALLENGE. OVEREXPRESSION OF GLYCINE TRANSPORTER 1 (GLYT1) IS PROPOSED AS A PATHOLOGICAL HALLMARK IN THE HIPPOCAMPUS OF PATIENTS WITH TEMPORAL LOBE EPILEPSY (TLE), AND WE PREVIOUSLY DEMONSTRATED IN RODENT EPILEPSY MODELS THAT AUGMENTATION OF GLYCINE SUPPRESSED CHRONIC SEIZURES AND ALTERED ACUTE SEIZURE THRESHOLDS. IN THE PRESENT STUDY WE EVALUATED THE EFFECT OF THE GLYT1 INHIBITOR, SARCOSINE (AKA N-METHYLGLYCINE), ON EPILEPTOGENESIS AND ALSO INVESTIGATED POSSIBLE MECHANISMS. WE DEVELOPED A MODIFIED RAPID KINDLING MODEL OF EPILEPTOGENESIS IN RATS COMBINED WITH SEIZURE SCORE MONITORING TO EVALUATE THE ANTIEPILEPTOGENIC EFFECT OF SARCOSINE. WE USED IMMUNOHISTOCHEMISTRY AND WESTERN BLOT ANALYSIS FOR THE EVALUATION OF GLYT1 EXPRESSION AND EPIGENETIC CHANGES OF 5-METHYLCYTOSINE (5MC) AND 5-HYDROXYMETHYLCYTOSINE (5HMC) IN THE EPILEPTOGENIC HIPPOCAMPI OF RATS, AND FURTHER EVALUATED EXPRESSION CHANGES IN ENZYMES INVOLVED IN THE REGULATION OF DNA METHYLATION, TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE 1 (TET1), DNA-METHYLTRANSFERASE 1 (DNMT1), AND DNMT3A. OUR RESULTS DEMONSTRATED: (I) EXPERIMENTAL EVIDENCE THAT SARCOSINE (3 G/KG, I.P. DAILY) SUPPRESSED KINDLING EPILEPTOGENESIS IN RATS; (II) THE SARCOSINE-INDUCED ANTIEPILEPTOGENIC EFFECT WAS ACCOMPANIED BY A SUPPRESSED HIPPOCAMPAL GLYT1 EXPRESSION AS WELL AS A REDUCTION OF HIPPOCAMPAL 5MC LEVELS AND A CORRESPONDING INCREASE IN 5HMC; AND (III) SARCOSINE TREATMENT CAUSED DIFFERENTIAL EXPRESSION CHANGES OF TET1 AND DNMTS. TOGETHER, THESE FINDINGS SUGGEST THAT SARCOSINE HAS UNPRECEDENTED DISEASE-MODIFYING PROPERTIES IN A KINDLING MODEL OF EPILEPTOGENESIS IN RATS, WHICH WAS ASSOCIATED WITH ALTERED HIPPOCAMPAL DNA METHYLATION. THUS, MANIPULATION OF THE GLYCINE SYSTEM IS A POTENTIAL THERAPEUTIC APPROACH TO ATTENUATE THE DEVELOPMENT OF EPILEPSY. 2020 17 1813 36 EFFECTS OF CAFFEIC ACID ON EPIGENETICS IN THE BRAIN OF RATS WITH CHRONIC UNPREDICTABLE MILD STRESS. THE PRESENT STUDY HYPOTHESIZED THAT CAFFEIC ACID (3,4?DIHYDROXYCINNAMIC ACID; CAA) MAY EXERT ANTIDEPRESSANT?LIKE EFFECTS IN RATS WITH CHRONIC UNPREDICTABLE MILD STRESS VIA EPIGENETIC MECHANISMS, SUCH AS DNA METHYLATION AND HYDROXYMETHYLATION. THE CHRONIC UNPREDICTABLE MILD STRESS (CUMS) MODEL WAS USED TO ANALYZE THE EFFECTS OF CAA ON BEHAVIORAL PHENOTYPES, AND TO EVALUATE THE DISTRIBUTION OF 5?METHYLCYTOSINE (5MC) AND 5?HYDROXYMETHYLCYTOSINE (5HMC) IN THE HIPPOCAMPUS AND PREFRONTAL CORTEX USING IMMUNOHISTOCHEMISTRY AND IMMUNOFLUORESCENCE. MRNA LEVELS OF THE GENES ENCODING BRAIN?DERIVED NEUROTROPIC FACTOR (BDNF) AND CATECHOL?O?METHYLTRANSFERASE (COMT), AND KEY ENZYMES REGULATING DNA METHYLATION [DNA METHYLTRANSFERASE (DNMT)1 AND DNMT3A] AND HYDROXYMETHYLATION [TEN?ELEVEN TRANSLOCATION (TET)1?3] WERE EXAMINED USING QUANTITATIVE (Q)PCR. FURTHERMORE, ENRICHMENT OF 5MC AND 5HMC AT THE PROMOTOR REGIONS OF THE BDNF AND COMT GENES WAS QUANTIFIED USING CHROMATIN IMMUNOPRECIPITATION?QPCR. BEHAVIORAL DATA SHOWED THAT CAA EXERTED A SLIGHT ANTIDEPRESSANT?LIKE EFFECT. BDNF AND COMT GENES SHOWED DIFFERENTIAL EXPRESSION PATTERNS DUE TO CUMS. CAA INTERVENTION INDUCED DIFFERENT DNMT1/DNMT3A AND TET1/TET2 MRNA LEVELS IN THE HIPPOCAMPUS AND PREFRONTAL CORTEX, RESPECTIVELY. CAA REGULATED THE RATIO OF 5MC/5HMC AT THE PROMOTOR REGION OF THE BDNF AND COMT GENES AND THEREFORE INFLUENCED GENE EXPRESSION, WHICH MAY BE A VALUABLE THERAPEUTIC OPTION FOR MAJOR DEPRESSIVE DISORDER (MDD). IN CONCLUSION, THERE WERE EPIGENETIC CHANGES IN THE HIPPOCAMPUS AND PREFRONTAL CORTEX IN CUMS RATS, AND CAA MAY FUNCTION AS A MODULATOR OF DNA METHYLATION TO REGULATE GENE TRANSCRIPTION, THUS PROVIDING A MECHANISTIC BASIS FOR THE USE OF THIS PHYTOCHEMICAL AGENT IN THE TREATMENT OF MDD. 2020 18 5971 27 TET PROTEINS AND 5-METHYLCYTOSINE OXIDATION IN HEMATOLOGICAL CANCERS. DNA METHYLATION HAS PIVOTAL REGULATORY ROLES IN MAMMALIAN DEVELOPMENT, RETROTRANSPOSON SILENCING, GENOMIC IMPRINTING, AND X-CHROMOSOME INACTIVATION. CANCER CELLS DISPLAY HIGHLY DYSREGULATED DNA METHYLATION PROFILES CHARACTERIZED BY GLOBAL HYPOMETHYLATION IN CONJUNCTION WITH HYPERMETHYLATION OF PROMOTER CPG ISLANDS THAT PRESUMABLY LEAD TO GENOME INSTABILITY AND ABERRANT EXPRESSION OF TUMOR SUPPRESSOR GENES OR ONCOGENES. THE RECENT DISCOVERY OF TEN-ELEVEN-TRANSLOCATION (TET) FAMILY DIOXYGENASES THAT OXIDIZE 5MC TO 5-HYDROXYMETHYLCYTOSINE (5HMC), 5-FORMYLCYTOSINE (5FC), AND 5-CARBOXYLCYTOSINE (5CAC) IN DNA HAS LED TO PROFOUND PROGRESS IN UNDERSTANDING THE MECHANISM UNDERLYING DNA DEMETHYLATION. AMONG THE THREE TET GENES, TET2 RECURRENTLY UNDERGOES INACTIVATING MUTATIONS IN A WIDE RANGE OF MYELOID AND LYMPHOID MALIGNANCIES. TET2 FUNCTIONS AS A BONA FIDE TUMOR SUPPRESSOR PARTICULARLY IN THE PATHOGENESIS OF MYELOID MALIGNANCIES RESEMBLING CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND MYELODYSPLASTIC SYNDROMES (MDS) IN HUMAN. HERE WE REVIEW DIVERSE FUNCTIONS OF TET PROTEINS AND THE NOVEL EPIGENETIC MARKS THAT THEY GENERATE IN DNA METHYLATION/DEMETHYLATION DYNAMICS AND NORMAL AND MALIGNANT HEMATOPOIETIC DIFFERENTIATION. THE IMPACT OF TET2 INACTIVATION IN HEMATOPOIESIS AND VARIOUS MECHANISMS MODULATING THE EXPRESSION OR ACTIVITY OF TET PROTEINS ARE ALSO DISCUSSED. FURTHERMORE, WE ALSO PRESENT EVIDENCE THAT TET2 AND TET3 COLLABORATE TO SUPPRESS ABERRANT HEMATOPOIESIS AND HEMATOPOIETIC TRANSFORMATION. A DETAILED UNDERSTANDING OF THE NORMAL AND PATHOLOGICAL FUNCTIONS OF TET PROTEINS MAY PROVIDE NEW AVENUES TO DEVELOP NOVEL EPIGENETIC THERAPIES FOR TREATING HEMATOLOGICAL MALIGNANCIES. 2015 19 83 31 A NOVEL EPIGENETIC MARKER, TEN-ELEVEN TRANSLOCATION FAMILY MEMBER 2 (TET2), IS IDENTIFIED IN THE INTRACTABLE EPILEPTIC BRAIN AND REGULATES ATP BINDING CASSETTE SUBFAMILY B MEMBER 1 (ABCB1) IN THE BLOOD-BRAIN BARRIER. DRUG-RESISTANT EPILEPSY (DRE) IS A CHRONIC CONDITION DERIVED FROM SPONTANEOUS CHANGES AND REGULATORY EFFECTS IN THE EPILEPTIC BRAIN. AS DEMETHYLATION FACTORS, TEN-ELEVEN TRANSLOCATION (TET) FAMILY MEMBERS HAVE BECOME A FOCUS IN RECENT STUDIES OF NEUROLOGICAL DISORDERS. HERE, WE QUANTIFIED AND LOCALIZED TET1, TET2 AND 5-HYDROXYMETHYLCYTOSINE (5-HMC) IN THE TEMPORAL LOBE CORTEX OF DRE PATIENTS (N = 27) AND TRAUMATIC BRAIN HEMORRHAGE CONTROLS (N = 10) BY IMMUNOCHEMICAL STAINING. TET2 AND ATP BINDING CASSETTE SUBFAMILY B MEMBER 1 (ABCB1) EXPRESSION PATTERNS WERE DETERMINED IN THE ISOLATED BRAIN CAPILLARIES OF DRE PATIENTS. TET2 EXPRESSION WAS SIGNIFICANTLY INCREASED IN THE TEMPORAL CORTICAL TISSUE OF DRE PATIENTS WITH OR WITHOUT HIPPOCAMPAL SCLEROSIS (HS) COMPARED TO CONTROL PATIENTS, WHILE TET1 AND 5-HMC SHOWED NO DIFFERENCES IN EXPRESSION. WE ALSO FOUND THAT A PARTICULARLY STRONG EXPRESSION OF TET2 IN THE VASCULAR TISSUE OF DRE PATIENTS. ABCB1 AND TET2 HAVE EVIDENTLY HIGHER EXPRESSION IN THE VASCULAR ENDOTHELIUM FROM THE NEOCORTEX OF DRE PATIENTS. IN BLOOD-BRAIN BARRIER (BBB) MODEL, TET2 DEPLETION CAN CAUSE ATTENUATED EXPRESSION AND FUNCTION OF ABCB1. DATA FROM A COHORT STUDY AND EXPERIMENTS IN A BBB MODEL SUGGEST THAT TET2 HAS A SPECIFIC REGULATORY EFFECT ON ABCB1, WHICH MAY SERVE AS A POTENTIAL MECHANISM AND TARGET IN DRE. 2022 20 5975 31 TET1 IS AN IMPORTANT TRANSCRIPTIONAL ACTIVATOR OF TNFALPHA EXPRESSION IN MACROPHAGES. ACTIVATION OF MACROPHAGES AND OVEREXPRESSION OF TNFALPHA IS ASSOCIATED WITH THE PATHOGENESIS OF CHRONIC INFLAMMATORY DISEASES. HOWEVER, THE MECHANISMS LEADING TO TNFALPHA OVEREXPRESSION ARE STILL UNKNOWN. 5-METHYLOCYTOSINE (5-MC) IS AN EPIGENETIC MODIFICATION THAT IS ASSOCIATED WITH SILENCED GENES. RECENT STUDIES SHOWED THAT IT IS CONVERTED TO 5-HYDROXYLMETHYLOCYTOSINE (5-HMC) AND REACTIVATES GENE EXPRESSION THROUGH THE ACTION OF THE FAMILY OF TEN-ELEVEN-TRANSLOCATION (TET1-3) ENZYMES. IN THIS STUDY, WE SHOW THAT 5-HMC LEVELS ARE INCREASED GLOBALLY AND SPECIFICALLY IN THE TNFALPHA PROMOTER DURING THE DIFFERENTIATION OF MONOCYTES TO MACROPHAGES. IN ADDITION, THE LEVELS OF 5-HMC ARE INCREASED UPON LPS STIMULATION OF MACROPHAGES. FURTHERMORE, CRIPSR STABLE KNOCKOUT OF TET1 DECREASES THE EXPRESSION OF TNFALPHA AND OTHER PRO-INFLAMMATORY CYTOKINES. IN CONCLUSION, WE SHOWED THAT TET1 CONTRIBUTES TO THE ACTIVATION OF MACROPHAGES POSSIBLY THROUGH REGULATION OF 5-HYDROXYMETHYLATION IN THE PROMOTER OF PRO-INFLAMMATORY CYTOKINE GENES. THE TET1 ENZYME COULD BE A PROMISING THERAPEUTIC TARGET TO INHIBIT THE PERSISTENT INFLAMMATION CAUSED BY MACROPHAGES IN CHRONIC INFLAMMATORY DISEASES. 2019